While no significant difference was observed between CAPA and COVID-19 control patients in MMP1 serum levels, our data reveal significantly lower IL-8 (p < 0.0001) and caspase-3 (p < 0.0001) serum levels in CAPA patients compared with COVID-19 control patients (Figure 6a). Here, CASP3 is linked to episodic ataxia type 2.